CTLA4 and melanoma: After a decade of clinical testing, Ipilimumab, an anti-CTLA-4 antibody, was proven to improve melanoma patient survival in a large Phase III clinical trial [11] and became the first checkpoint inhibitor approved by the FDA for advanced melanoma [12].